MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- Aerogen, Inc. and MAQUET Critical Care AB ("MAQUET"), a company of GETINGE AB, today announced they have entered into a worldwide, non-exclusive distribution agreement for Aerogen's Aeroneb(R) Professional Nebulizer System ("Aeroneb Pro"). Under the agreement, MAQUET will market and distribute the Aeroneb Pro for use with its new and existing Servo ventilators. The Aeroneb Pro incorporates Aerogen's proprietary OnQ(TM) Aerosol Generator, which offers the potential to improve the efficiency of pulmonary drug delivery and reduce drug and personnel costs associated with in-patient care.
"MAQUET is committed to advancing patient care solutions in the critical care setting," commented Nils Rosen, Vice President Marketing for MAQUET Critical Care. "Aerogen's technology can impact the efficiency of pulmonary drug delivery, and is a good fit with our product portfolio of ventilation systems."
"We are pleased that MAQUET, a leading ventilator manufacturer, has selected Aerogen's Aeroneb Pro as its new standard option for aerosolization of medication to ventilated patients," commented Dr. Jane Shaw, Aerogen Chairman and Chief Executive Officer. "This partnership will expand caregiver access to this improved standard of care."
GETINGE AB is one of the world's leading providers of technical equipment and systems for use in the pharmaceutical industry, medical surgery, intensive and extended care facilities. Following recent acquisitions, GETINGE AB now employs some 6,600 staff worldwide. In 2003, it posted sales of 991 million euros (SEK 9.1 bn). MAQUET is one of the leading international providers of medical products in the field of operating rooms and intensive care. Based in Solna near Stockholm, MAQUET is a major supplier of advanced ventilation systems, which improve patient outcomes in the expanding critical care market. More information can be found on the web at http://www.maquet.com/criticalcare and http://www.getinge.com/.
Aerogen, a specialty pharmaceutical company, develops products based on its OnQ(TM) Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen currently markets the Aeroneb(R) Professional Nebulizer System for use in hospitals. Aerogen has presented the results of a Phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. In the U.S., Aerogen has commercialized the Aeroneb(R) Go Nebulizer for home use through it's commercial partner. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.
To the extent any statements made in this release relate to information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of the Company's control and other uncertainties, and are subject to various risk factors that could cause the Company's actual results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the need for additional funding, the inherent risks of product development, clinical outcomes, regulatory risks and risks related to proprietary rights, market acceptance and competition, and are described in the Company's reports and other filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission ("SEC") on April 14, 2004, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2004, filed with the SEC on May 13, 2004 and its Registration Statement on Form S-3 filed with the SEC on May 24, 2004. Aerogen does not undertake any obligation to update forward-looking statements.
Aerogen, Inc.
"MAQUET is committed to advancing patient care solutions in the critical care setting," commented Nils Rosen, Vice President Marketing for MAQUET Critical Care. "Aerogen's technology can impact the efficiency of pulmonary drug delivery, and is a good fit with our product portfolio of ventilation systems."
"We are pleased that MAQUET, a leading ventilator manufacturer, has selected Aerogen's Aeroneb Pro as its new standard option for aerosolization of medication to ventilated patients," commented Dr. Jane Shaw, Aerogen Chairman and Chief Executive Officer. "This partnership will expand caregiver access to this improved standard of care."
GETINGE AB is one of the world's leading providers of technical equipment and systems for use in the pharmaceutical industry, medical surgery, intensive and extended care facilities. Following recent acquisitions, GETINGE AB now employs some 6,600 staff worldwide. In 2003, it posted sales of 991 million euros (SEK 9.1 bn). MAQUET is one of the leading international providers of medical products in the field of operating rooms and intensive care. Based in Solna near Stockholm, MAQUET is a major supplier of advanced ventilation systems, which improve patient outcomes in the expanding critical care market. More information can be found on the web at http://www.maquet.com/criticalcare and http://www.getinge.com/.
Aerogen, a specialty pharmaceutical company, develops products based on its OnQ(TM) Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen currently markets the Aeroneb(R) Professional Nebulizer System for use in hospitals. Aerogen has presented the results of a Phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. In the U.S., Aerogen has commercialized the Aeroneb(R) Go Nebulizer for home use through it's commercial partner. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.
To the extent any statements made in this release relate to information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of the Company's control and other uncertainties, and are subject to various risk factors that could cause the Company's actual results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the need for additional funding, the inherent risks of product development, clinical outcomes, regulatory risks and risks related to proprietary rights, market acceptance and competition, and are described in the Company's reports and other filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission ("SEC") on April 14, 2004, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2004, filed with the SEC on May 13, 2004 and its Registration Statement on Form S-3 filed with the SEC on May 24, 2004. Aerogen does not undertake any obligation to update forward-looking statements.
Aerogen, Inc.
© 2004 PR Newswire
